Table 2.
Prevalence of pretreatment HIV drug resistance by provincial-level administrative divisions in 2022 in China.
| Province | Prevalence, n (%) | Participants (n=2568), n | ||||
|
|
PR/RTa (n=190) | NNRTIsb (n=163) | NRTIsc (n=32) | PIsd (n=5) |
|
|
| Hebei | 13 (7.4) | 9 (5.1) | 4 (2.3) | 0 (0) | 175 | |
| Jilin | 19 (9.2) | 17 (8.2) | 4 (1.9) | 0 (0) | 206 | |
| Jiangsu | 24 (7.2) | 22 (6.5) | 1 (0.2) | 1 (0.2) | 335 | |
| Zhejiang | 34 (8.8) | 27 (7) | 7 (1.8) | 0 (0) | 385 | |
| Hubei | 20 (5.5) | 19 (5.2) | 1 (0.2) | 0 (0) | 362 | |
| Chongqing | 20 (5.3) | 14 (3.7) | 7 (1.8) | 1 (0.2) | 378 | |
| Sichuan | 17 (4.9) | 16 (4.5) | 0 (0) | 1 (0.2) | 350 | |
| Yunnan | 43 (11.4) | 39 (10.3) | 8 (2.1) | 2 (0.5) | 377 | |
| All provinces | 190 (7.4) | 163 (6.3) | 32 (1.2) | 5 (0.2) | 2568 | |
aPR/RT: protease and reverse transcriptase.
bNNRTIs: nonnucleoside reverse transcriptase inhibitors.
cNRTIs: nucleoside reverse transcriptase inhibitors.
dPIs: protease inhibitors.